SCYNEXIS Reports First Quarter 2025 Financial Results and Provides Corporate Update
Written by Emily J. Thompson, Senior Investment Analyst
Updated: May 15 2025
0mins
Source: Globenewswire
FDA Developments: The FDA lifted the clinical hold on ibrexafungerp, allowing SCYNEXIS to resume the Phase 3 MARIO study for invasive candidiasis, despite a disagreement with GSK regarding the study's continuation. Hansoh has also received approval in China for ibrexafungerp, which will provide SCYNEXIS with milestone payments and royalties.
Financial Overview: SCYNEXIS reported a net loss of $5.4 million for Q1 2025, with cash reserves of $53.8 million expected to last until Q3 2026. The company is advancing its second-generation fungicide candidate, SCY-247, with initial Phase 1 data anticipated in Q3 2025.
Discover Tomorrow's Bullish Stocks Today
Receive free daily stock recommendations and professional analysis to optimize your portfolio's potential.
Sign up now to unlock expert insights and stay one step ahead of the market trends.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
